Disclosed positions
| INVESCO DB COMMDY INDX TRCK | DBC | UNIT | $28,185,965 | 1,057,238 | SH | None |
| ABIVAX SA | ABVX | SPONSORED ADS | $15,062,511 | 113,031 | SH | None |
| REVOLUTION MEDICINES INC | RVMD | COM | $12,544,576 | 66,983 | SH | None |
| DEFINIUM THERAPEUTICS INC | DFTX | COM SHS | $11,425,263 | 242,884 | SH | None |
| IMMUNOVANT INC | IMVT | COM | $10,706,447 | 277,873 | SH | None |
| PRAXIS PRECISION MEDICINES I | PRAX | COM NEW | $10,114,006 | 30,210 | SH | None |
| RELAY THERAPEUTICS INC | RLAY | COM | $9,471,675 | 506,235 | SH | None |
| ALKERMES PLC | ALKS | SHS | $9,392,118 | 179,256 | SH | None |
| VAXCYTE INC | PCVX | COM | $8,704,329 | 149,739 | SH | None |
| TANGO THERAPEUTICS INC | TNGX | COM | $8,129,788 | 260,070 | SH | None |
| LIQUIDIA CORPORATION | LQDA | COM NEW | $7,805,248 | 97,896 | SH | None |
| COGENT BIOSCIENCES INC | COGT | COM | $7,305,786 | 188,780 | SH | None |
| STRUCTURE THERAPEUTICS INC | GPCR | SPONSORED ADS | $7,019,177 | 130,784 | SH | None |
| ENLIVEN THERAPEUTICS INC | ELVN | COM | $6,996,700 | 137,866 | SH | None |
| AMYLYX PHARMACEUTICALS INC | AMLX | COM | $6,933,997 | 386,080 | SH | None |
| SPYRE THERAPEUTICS INC | SYRE | COM NEW | $6,907,706 | 77,807 | SH | None |
| LB PHARMACEUTICALS INC | LBRX | COM SHS | $6,864,590 | 211,511 | SH | None |
| CYTOKINETICS INC | CYTK | COM NEW | $6,645,076 | 78,003 | SH | None |
| C4 THERAPEUTICS INC | CCCC | COM STK | $6,295,800 | 1,348,136 | SH | None |
| TYRA BIOSCIENCES INC | TYRA | COM | $5,901,681 | 184,774 | SH | None |
| ALUMIS INC | ALMS | COM | $5,627,100 | 199,968 | SH | None |
| PHARVARIS N V | PHVS | COM | $5,549,882 | 160,494 | SH | None |
| TARSUS PHARMACEUTICALS INC | TARS | COM | $5,479,557 | 87,060 | SH | None |
| COMPASS PATHWAYS PLC | CMPS | SPONSORED ADS | $5,251,349 | 371,120 | SH | None |
| DIANTHUS THERAPEUTICS INC | DNTH | COM | $4,983,665 | 51,125 | SH | None |
| NURIX THERAPEUTICS INC | NRIX | COM | $4,942,709 | 203,739 | SH | None |
| AXSOME THERAPEUTICS INC. | AXSM | COM | $4,940,193 | 20,183 | SH | None |
| TRAVERE THERAPEUTICS INC | TVTX | COM | $4,898,896 | 86,233 | SH | None |
| VERA THERAPEUTICS INC | VERA | CL A | $4,544,470 | 105,907 | SH | None |
| NVIDIA CORPORATION | NVDA | COM | $4,360,361 | 21,792 | SH | None |
| GH RESEARCH PLC | GHRS | ORDINARY SHARES | $4,267,737 | 158,770 | SH | None |
| PALISADE BIO INC | PALI | COM | $4,244,638 | 2,030,927 | SH | None |
| ARGENX SE | ARGX | SPONSORED ADR | $4,231,559 | 4,561 | SH | None |
| MAZE THERAPEUTICS INC | MAZE | COM | $4,075,308 | 136,572 | SH | None |
| OCULAR THERAPEUTIX INC | OCUL | COM | $4,011,804 | 408,534 | SH | None |
| ORUKA THERAPEUTICS INC | ORKA | COM | $3,987,813 | 41,902 | SH | None |
| DYNE THERAPEUTICS INC | DYN | COM | $3,819,254 | 171,961 | SH | None |
| EDGEWISE THERAPEUTICS INC | EWTX | COM | $3,697,168 | 90,996 | SH | None |
| MOONLAKE IMMUNOTHERAPEUTICS | MLTX | CLASS A ORD | $3,659,308 | 187,946 | SH | None |
| INSMED INC | INSM | COM PAR $.01 | $3,332,515 | 31,256 | SH | None |
| CELLDEX THERAPEUTICS INC NEW | CLDX | COM NEW | $3,235,930 | 86,964 | SH | None |
| AMAZON COM INC | AMZN | COM | $3,193,041 | 13,397 | SH | None |
| INVENTIVA SA | IVA | ADS | $3,142,851 | 831,442 | SH | None |
| TALEN ENERGY CORP | TLN | COM | $3,130,951 | 8,148 | SH | None |
| RELMADA THERAPEUTICS INC | RLMD | COM | $3,084,929 | 445,799 | SH | None |
| PROTAGONIST THERAPEUTICS INC | PTGX | COM | $2,998,307 | 24,460 | SH | None |
| ERASCA INC | ERAS | COM | $2,937,208 | 160,328 | SH | None |
| VIRIDIAN THERAPEUTICS INC | VRDN | COM | $2,937,087 | 159,885 | SH | None |
| HEWLETT PACKARD ENTERPRISE C | HPE | COM | $2,665,143 | 59,081 | SH | None |
| MINERALYS THERAPEUTICS INC | MLYS | COM | $2,322,573 | 86,085 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 0 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.